Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer

Expert Opinion on Investigational Drugs

Volumn 19, Issue 6, 2010, Pages 777-788

  Schultze, Alexander ^a   Fiedler, Walter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Angiogenesis; Chemoresistance; Clinical trial; FAK; FAK inhibitor; Pyk2

Indexed keywords

1,2,4,5 BENZENETETRAAMINE TETRAHYDROCHLORIDE; ANTHRACYCLINE DERIVATIVE; BOSUTINIB; CISPLATIN; DASATINIB; ETOPOSIDE; FLUOROURACIL; FOCAL ADHESION KINASE 2; FOCAL ADHESION KINASE INHIBITOR; GC 1008; GEMCITABINE; GSK 2256098; NVP TAC 544; NVP TAE 226; PF 03446962; PF 04554878; PF 562271; PF 573228; PLACEBO; SHORT HAIRPIN RNA; SUNITINIB; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADVANCED CANCER; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER RESISTANCE; CANCER THERAPY; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG STRUCTURE; ESOPHAGUS CANCER; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GLIOMA; HEAD AND NECK CANCER; HUMAN; LIVER CELL CARCINOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERIPHERAL EDEMA; PROGNOSIS; PROSTATE CANCER; REVIEW; RNA INTERFERENCE; SOLID TUMOR; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77952469195     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.489548     Document Type: Review

References (100)

1. Otey CA, Burridge K. Patterning of the membrane cytoskeleton by the extracellular matrix. Semin Cell Biol 1990;1(5):391-399
2. Schlaepfer DD, Mitra SK, Ilic D. Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 2004;1692(2-3):77-102
3. Zachary I, Rozengurt E. Focal adhesion kinase (p125FAK): a point of convergence in the action of neuropeptides, integrins, and oncogenes. Cell 1992;71(6):891-894
4. Kornberg L, Earp HS, Parsons JT, et al. Cell adhesion or integrin clustering increases phosphorylation of a focal adhesion-associated tyrosine kinase. J Biol Chem 1992;267(33):23439-23442
5. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124(4):619-626
6. Owens LV, Xu L, Craven RJ, et al. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res 1995;55(13):2752-2755
7. Weiner TM, Liu ET, Craven RJ, Cance WG. Expression of focal adhesion kinase gene and invasive cancer. Lancet 1993;342(8878):1024-1025
8. Ilic D, Kovacic B, McDonagh S, et al. Focal adhesion kinase is required for blood vessel morphogenesis. Circ Res 2003;92(3):300-307
9. Lahlou H, Sanguin-Gendreau V, Zuo D, et al. Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci USA 2007;104(51):20302-20307
10. Provenzano PP, Inman DR, Eliceiri KW, et al. Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer. Am J Pathol 2008;173(5):1551-1565
11. Schaller MD, Borgman CA, Cobb BS, et al. pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA 1992;89(11):5192-5196
12. Kanner SB, Reynolds AB, Vines RR, Parsons JT. Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc Natl Acad Sci USA 1990;87(9):3328-3332
13. Burridge K, Turner CE, Romer LH. Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. J Cell Biol 1992;119(4):893-903
14. Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 2009;28(1-2):35-49
15. Schaller MD. Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta 2001;1540(1):1-21
16. Walsh C, Tanjoni I, Uryu S, et al. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol Ther 2010;9(10). [Epub ahead of print]
17. Chatzizacharias NA, Kouraklis GP, Theocharis SE. Focal adhesion kinase: a promising target for anticancer therapy. Expert Opin Ther Targets 2007;11(10):1315-1328
18. Han EK, McGonigal T. Role of focal adhesion kinase in human cancer: a potential target for drug discovery. Anticancer Agents Med Chem 2007;7(6):681-684
19. van Nimwegen MJ, van de Water B. Focal adhesion kinase: a potential target in cancer therapy. Biochem Pharmacol 2007;73(5):597-609
20. Parsons JT, Slack-Davis J, Tilghman R, Roberts WG. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res 2008;14(3):627-632
21. Sasaki H, Nagura K, Ishino M, et al. Cloning and characterization of cell adhesion kinase beta, a novel protein-tyrosine kinase of the focal adhesion kinase subfamily. J Biol Chem 1995;270(36):21206-21219
22. Avraham H, Park SY, Schinkmann K, Avraham S. RAFTK/Pyk2-mediated cellular signalling. Cell Signal 2000;12(3):123-133
23. Orr AW, Murphy-Ullrich JE. Regulation of endothelial cell function BY FAK and PYK2. Front Biosci 2004;9:1254-1266
24. Fujii T, Koshikawa K, Nomoto S, et al. Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor. J Hepatol 2004;41(1):104-111
25. Yuan Z, Fan J, Wu ZQ, et al. Focal adhesion kinase mRNA overexpression in hepatocellular carcinoma HCC) and correlation thereof with prognosis of HCC. Zhonghua Yi Xue Za Zhi 2007;87(18):1256-1259
26. Lark AL, Livasy CA, Dressler L, et al. High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod Pathol 2005;18(10):1289-1294
27. Giaginis CT, Vgenopoulou S, Tsourouflis GS, et al. Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma. Pathol Oncol Res 2009;15(2):173-181
28. Gabriel B, Hasenburg A, Waizenegger M, et al. Expression of focal adhesion kinase in patients with endometrial cancer: a clinicopathologic study. Int J Gynecol Cancer 2009;19(7):1221-1225
29. Tavernier-Tardy E, Cornillon J, Campos L, et al. Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia. Leuk Res 2009;33(6):764-768
30. Schmitz KJ, Grabellus F, Callies R, et al. High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome. Breast Cancer Res 2005;7(2):R194-203
31. Theocharis SE, Kouraklis GP, Kakisis JD, et al. Focal adhesion kinase expression is not a prognostic predictor in colon adenocarcinoma patients. Eur J Surg Oncol 2003;29(7):571-574
32. Furuyama K, Doi R, Mori T, et al. Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J Surg 2006;30(2):219-226
33. Gabriel B, zur Hausen A, Stickeler E, et al. Weak expression of focal adhesion kinase (pp125FAK) in patients with cervical cancer is associated with poor disease outcome. Clin Cancer Res 2006;12(8):2476-2483
34. Ayaki M, Komatsu K, Mukai M, et al. Reduced expression of focal adhesion kinase in liver metastases compared with matched primary human colorectal adenocarcinomas. Clin Cancer Res 2001;7(10):3106-3112
35. Golubovskaya VM, Zheng M, Zhang L, et al. The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis. BMC Cancer 2009;9:280
36. Schaller MD, Borgman CA, Parsons JT. Autonomous expression of a noncatalytic domain of the focal adhesion-associated protein tyrosine kinase pp125FAK. Mol Cell Biol 1993;13(2):785-791
37. Schwock J, Dhani N, Cao MP, et al. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts. Cancer Res 2009;69(11):4750-4759
38. Zheng Y, Lu Z. Paradoxical roles of FAK in tumor cell migration and metastasis. Cell Cycle 2009;8(21):3474-3479
39. Folkman J. Angiogenesis: initiation and modulation. Symp Fundam Cancer Res 1983;36:201-208
40. Kawaguchi T, Nakamura K. Cancer metastasis and blood vessels. Gan To Kagaku Ryoho 1983;10(7):1569-1576
41. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9(6):653-660
42. Gehling UM, Ergun S, Schumacher U, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000;95(10):3106-3112
43. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004;104(9):2752-2760
44. Ilic D, Furuta Y, Kanazawa S, et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 1995;377(6549):539-544
45. Furuta Y, Ilic D, Kanazawa S, et al. Mesodermal defect in late phase of gastrulation by a targeted mutation of focal adhesion kinase, FAK. Oncogene 1995;11(10):1989-1995
46. Ilic D, Furuta Y, Suda T, et al. Focal adhesion kinase is not essential for in vitro and in vivo differentiation of ES cells. Biochem Biophys Res Commun 1995;209(1):300-309
47. Shen TL, Park AY, Alcaraz A, et al. Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol 2005;169(6):941-952
48. Braren R, Hu H, Kim YH, et al. Endothelial FAK is essential for vascular network stability, cell survival, and lamellipodial formation. J Cell Biol 2006;172(1):151-162
49. Peng X, Ueda H, Zhou H, et al. Overexpression of focal adhesion kinase in vascular endothelial cells promotes angiogenesis in transgenic mice. Cardiovasc Res 2004;64(3):421-430
50. Huang YD, Zhang S. Focal adhesion kinase expression and angiogenesis in breast carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 2007;27(9):1370-1373
51. Dechantsreiter MA, Planker E, Matha B, et al. N-Methylated cyclic RGD peptides as highly active and selective alpha(V) beta(3) integrin antagonists. J Med Chem 1999;42(16):3033-3040
52. Loges S, Butzal M, Otten J, et al. Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Biochem Biophys Res Commun 2007;357(4):1016-1020
53. Nisato RE, Tille JC, Jonczyk A, et al. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003;6(2):105-119
54. Oliveira-Ferrer L, Hauschild J, Fiedler W, et al. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res 2008;27:86
55. Schultze A, Decker S, Otten J, et al. TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis. Invest New Drugs 2009. [Epub ahead of print]
56. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-231
57. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15(3):232-239
58. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol; 12(3):233-242
59. Weis SM, Lim ST, Lutu-Fuga KM, et al. Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. J Cell Biol 2008;181(1):43-50
60. Sieg DJ, Ilic D, Jones KC, et al. Pyk2 and Src-family protein-tyrosine kinases compensate for the loss of FAK in fibronectin-stimulated signaling events but Pyk2 does not fully function to enhance FAK-cell migration. EMBO J 1998;17(20):5933-5947
61. Lipinski CA, Loftus JC. Targeting Pyk2 for therapeutic intervention. Expert Opin Ther Targets 2010;14(1):95-108
62. Lim ST, Mikolon D, Stupack DG, Schlaepfer DD. FERM control of FAK function: implications for cancer therapy. Cell Cycle 2008;7(15):2306-2314
63. Bogoyevitch MA, Fairlie DP. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov Today 2007;12(15-16):622-633
64. Han S, Mistry A, Chang JS, et al. Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor design. J Biol Chem 2009;284(19):13193-13201
65. Slack-Davis JK, Martin KH, Tilghman RW, et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 2007;282(20):14845-14852
66. Roberts WG, Ung E, Whalen P, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 2008;68(6):1935-1944
67. Siu LL BL, Mileshkin L, Camidge DR, et al. Phase 1 study of a focal adhesion kinase (FAK) inhibitor PF-00562271 in patients (pts) with advanced solid tumors. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):abstract 3527
68. Siu LL BH, Mileshkin LR, Camidge DR, et al. A phase I clinical, pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with advanced solid tumors. 2008 ASCO Annual Meeting. J Clin Oncol 2008;26:abstract 3534
69. Shi Q, Hjelmeland AB, Keir ST, et al. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog 2007;46(6):488-496
70. Liu TJ, LaFortune T, Honda T, et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 2007;6(4):1357-1367
71. Golubovskaya VM, Virnig C, Cance WG. TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR. Mol Carcinog 2008;47(3):222-234
72. Halder J, Lin YG, Merritt WM, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007;67(22):10976-10983
73. Beierle EA, Trujillo A, Nagaram A, et al. TAE226 inhibits human neuroblastoma cell survival. Cancer Invest 2008;26(2):145-151
74. Watanabe N, Takaoka M, Sakurama K, et al. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo. Clin Cancer Res 2008;14(14):4631-4639
75. Wang ZG, Fukazawa T, Nishikawa T, et al. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells. Oncol Rep 2008;20(6):1473-1477
76. Sakurama K, Noma K, Takaoka M, et al. Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor. Mol Cancer Ther 2009;8(1):127-134
77. Din S. EORTC-NCI-AACR-20th symposium molecular targets and cancer therapeutics. IDrugs 2008;11(12):855-856
78. Golubovskaya VM, Nyberg C, Zheng M, et al. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 2008;51(23):7405-7416
79. Hochwald SN, Nyberg C, Zheng M, et al. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle 2009;8(15):2435-2443
80. Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007;25(9):1035-1044
81. Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 2010;36(2):177-184
82. Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009;15(23):7421-7428
83. Duxbury MS, Ito H, Benoit E, et al. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun 2003;311(3):786-792
84. Huanwen W, Zhiyong L, Xiaohua S, et al. Intrinsic chemoresistance to Gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer 2009;8:125
85. Chen YY, Wang ZX, Chang PA, et al. Knockdown of focal adhesion kinase reverses colon carcinoma multicellular resistance. Cancer Sci 2009;100(9):1708-1713
86. Chen Y, Wang Z, Chang P, et al. The effect of focal adhesion kinase gene silencing on 5-fluorouracil chemosensitivity involves an Akt/NF-kappaB signaling pathway in colorectal carcinomas. Int J Cancer 2010;127(1):195-206
87. Zhang HM, Keledjian KM, Rao JN, et al. Induced focal adhesion kinase expression suppresses apoptosis by activating NF-kappaB signaling in intestinal epithelial cells. Am J Physiol Cell Physiol 2006;290(5):C1310-20
88. Smith CS, Golubovskaya VM, Peck E, et al. Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. Melanoma Res 2005;15(5):357-362
89. Halder J, Kamat AA, Landen CN, et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006;12(16):4916-4924
90. Wu ZM, Yuan XH, Jiang PC, et al. Antisense oligonucleodes targeting the focal adhesion kinase inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human glioma cells. J Neurooncol 2006;77(2):117-123
91. van Nimwegen MJ, Huigsloot M, Camier A, et al. Focal adhesion kinase and protein kinase B cooperate to suppress doxorubicin-induced apoptosis of breast tumor cells. Mol Pharmacol 2006;70(4):1330-1339
92. Sonoda Y, Matsumoto Y, Funakoshi M, et al. Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J Biol Chem 2000;275(21):16309-16315
93. Golubovskaya VM, Gross S, Kaur AS, et al. Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis in colon cancer cell lines. Mol Cancer Res 2003;1(10):755-764
94. Beierle EA, Ma X, Trujillo A, et al. Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines. Mol Carcinog 2010;49(3):224-234
95. Garamszegi N, Garamszegi SP, Samavarchi-Tehrani P, et al. Extracellular matrix-induced transforming growth factor-beta receptor signaling dynamics. Oncogene 2010;29(16):2368-2380
96. Wendt MK, Schiemann WP. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res 2009;11(5):R68
97. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9(1):327-337
98. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101(9):3597-3605
99. Bagi CM, Christensen J, Cohen DP, et al. Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model. Cancer Biol Ther 2009;8(9):856-865
100. Schmidmaier R, Baumann P. ANTI-ADHESION evolves to a promising therapeutic concept in oncology. Curr Med Chem 2008;15(10):978-990